more attention focused on urinary incontinence

February 1999

You'll see more attention focused on urinary incontinence.

This is a big problem. More than 15 million people suffer from bladder problems...only about 10% seek help.

This attention is partly fueled by ads for two new drugs...Ditropan XL (oxybutynin) and Detrol (tolterodine). These drugs inhibit bladder contractions and delay the desire to void.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

drug reps to give out information about unapproved uses of their prescription drugs
Celebrex (celecoxib), the first COX-2 selective NSAID to hit the market
Neurology & Pain new CNS stimulant called Provigil (modafinil)
Lovenox (enoxaparin) is now approved to TREAT blood clots
new drug for intermittent claudication
Gastroenterology new guidelines for treating H. pylori
Diabetes Glyset (miglitol), a new drug for type 2 diabetes
Diabetes mix Humalog (lispro) with long-acting insulins
Diabetes Fenugreek supplements (Limitrol-DM, etc) are now being promoted to lower blood sugar
Women's Health Prometrium (micronized progesterone) is now APPROVED for hormone replacement therapy (HRT)
Women's Health more attention focused on urinary incontinence
new drug for HIV, Ziagen (abacavir)
Infectious Diseases Lymerix, the first vaccine to prevent Lyme disease
Infectious Diseases minocycline is useful for mild to moderate scleroderma
Infectious Diseases Herp-Eeze, a new herbal supplement promoted for herpes
Generics two significant new generics
Practice chart of new drugs approved by the FDA in 1998

more attention focused on urinary incontinence

Practical advice for a better career, with unlimited access to CE

Table of Contents